These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2439 related articles for article (PubMed ID: 7750125)
21. Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells. Mangino G; Grazia Capri M; Barnaba V; Alberti S Int J Cancer; 2002 Oct; 101(4):353-9. PubMed ID: 12209960 [TBL] [Abstract][Full Text] [Related]
22. Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Mortarini R; Anichini A; Di Nicola M; Siena S; Bregni M; Belli F; Molla A; Gianni AM; Parmiani G Cancer Res; 1997 Dec; 57(24):5534-41. PubMed ID: 9407964 [TBL] [Abstract][Full Text] [Related]
23. Human monocyte-derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class I-restricted exogenous peptides. Toujas L; Delcros JG; Diez E; Gervois N; Semana G; Corradin G; Jotereau F Immunology; 1997 Aug; 91(4):635-42. PubMed ID: 9378506 [TBL] [Abstract][Full Text] [Related]
24. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041 [TBL] [Abstract][Full Text] [Related]
25. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Rivoltini L; Barracchini KC; Viggiano V; Kawakami Y; Smith A; Mixon A; Restifo NP; Topalian SL; Simonis TB; Rosenberg SA Cancer Res; 1995 Jul; 55(14):3149-57. PubMed ID: 7541714 [TBL] [Abstract][Full Text] [Related]
26. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. Godelaine D; Carrasco J; Lucas S; Karanikas V; Schuler-Thurner B; Coulie PG; Schuler G; Boon T; Van Pel A J Immunol; 2003 Nov; 171(9):4893-7. PubMed ID: 14568970 [TBL] [Abstract][Full Text] [Related]
27. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Bakker AB; Marland G; de Boer AJ; Huijbens RJ; Danen EH; Adema GJ; Figdor CG Cancer Res; 1995 Nov; 55(22):5330-4. PubMed ID: 7585596 [TBL] [Abstract][Full Text] [Related]
28. Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma. Philip R; Alters SE; Brunette E; Ashton J; Gadea J; Yau J; Lebkowski J; Philip M J Immunother; 2000 Jan; 23(1):168-76. PubMed ID: 10687150 [TBL] [Abstract][Full Text] [Related]
29. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. Bellone M; Iezzi G; Manfredi AA; Protti MP; Dellabona P; Casorati G; Rugarli C Eur J Immunol; 1994 Nov; 24(11):2691-8. PubMed ID: 7525300 [TBL] [Abstract][Full Text] [Related]
30. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302 [TBL] [Abstract][Full Text] [Related]
31. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. van der Bruggen P; Bastin J; Gajewski T; Coulie PG; Boël P; De Smet C; Traversari C; Townsend A; Boon T Eur J Immunol; 1994 Dec; 24(12):3038-43. PubMed ID: 7805731 [TBL] [Abstract][Full Text] [Related]
32. T cell recognition of melanoma antigens in association with HLA-A1 on allogeneic melanoma cells. Chen Q; Smith M; Nguyen T; Maher DW; Hersey P Cancer Immunol Immunother; 1994 Jun; 38(6):385-93. PubMed ID: 8205560 [TBL] [Abstract][Full Text] [Related]
33. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. van der Bruggen P; Szikora JP; Boël P; Wildmann C; Somville M; Sensi M; Boon T Eur J Immunol; 1994 Sep; 24(9):2134-40. PubMed ID: 7522162 [TBL] [Abstract][Full Text] [Related]
34. Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1. Romero P; Pannetier C; Herman J; Jongeneel CV; Cerottini JC; Coulie PG J Exp Med; 1995 Oct; 182(4):1019-28. PubMed ID: 7561675 [TBL] [Abstract][Full Text] [Related]
35. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. Tüting T; Wilson CC; Martin DM; Kasamon YL; Rowles J; Ma DI; Slingluff CL; Wagner SN; van der Bruggen P; Baar J; Lotze MT; Storkus WJ J Immunol; 1998 Feb; 160(3):1139-47. PubMed ID: 9570527 [TBL] [Abstract][Full Text] [Related]
36. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Bernhard H; Disis ML; Heimfeld S; Hand S; Gralow JR; Cheever MA Cancer Res; 1995 Mar; 55(5):1099-104. PubMed ID: 7532543 [TBL] [Abstract][Full Text] [Related]
37. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. Van den Eynde B; Peeters O; De Backer O; Gaugler B; Lucas S; Boon T J Exp Med; 1995 Sep; 182(3):689-98. PubMed ID: 7544395 [TBL] [Abstract][Full Text] [Related]
38. Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities. Riley JP; Rosenberg SA; Parkhurst MR J Immunol Methods; 2003 May; 276(1-2):103-19. PubMed ID: 12738363 [TBL] [Abstract][Full Text] [Related]
39. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44. Godelaine D; Carrasco J; Brasseur F; Neyns B; Thielemans K; Boon T; Van Pel A Cancer Immunol Immunother; 2007 Jun; 56(6):753-9. PubMed ID: 17096150 [TBL] [Abstract][Full Text] [Related]
40. Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide. Matsunaga K; Nakao M; Masuoka K; Inoue Y; Gouhara R; Imaizumi T; Nishizaka S; Itoh K Jpn J Cancer Res; 1999 Sep; 90(9):1007-15. PubMed ID: 10551332 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]